Brookline Capital Management upgraded shares of Medicus Pharma (NASDAQ:MDCX – Free Report) to a strong-buy rating in a report issued on Monday,Zacks.com reports.
Separately, Maxim Group began coverage on Medicus Pharma in a research note on Tuesday, December 17th. They issued a “buy” rating and a $10.00 price objective on the stock.
Get Our Latest Stock Report on MDCX
Medicus Pharma Stock Performance
Medicus Pharma Company Profile
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Further Reading
- Five stocks we like better than Medicus Pharma
- When to Sell a Stock for Profit or Loss
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- What Are Earnings Reports?
- 2 Drone Stocks Surging from Increased Media Attention
- Market Cap Calculator: How to Calculate Market Cap
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
